Product logins

Find logins to all Clarivate products below.


Insomnia | Treatment Algorithms: Claims Data Analysis | US | 2022

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting an appropriate therapeutic. The primary goal of treatment is to improve patients’ quality of sleep, with minimal next-day side effects. While generics are entrenched in the treatment algorithm, the branded dual orexin receptor antagonists Belsomra (Merck) and Dayvigo (Eisai) provide a new mechanism of action for patients in later lines of therapy, and additional agents in the class are progressing through the pipeline or are poised to launch in the U.S. market. Therefore, understanding the use of current therapies among newly diagnosed and recently treated insomnia patients is essential to optimizing the uptake of branded therapies.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed insomnia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed insomnia patients?
  • How have Belsomra and Dayvigo been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of insomnia patients receive a prescription drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of insomnia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Content highlights

Geographies: United States.

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Belsomra, Dayvigo, Edluar, Zolpimist, zolpidem IR, zolpidem CR, eszopiclone, trazodone, Rozerem, ramelteon, zaleplon, doxepin, benzodiazepines.

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…